Patient Considerations to Guide Biologic Treatment Selection in Atopic Dermatitis
April 21, 2025
Panelists discuss how selecting a biologic for atopic dermatitis involves comprehensive assessment of patient-specific factors including age (with dupilumab's broader approval for patients as young as 6 months vs other biologics approved only for those aged 12 years or older), weight (affecting dosing considerations), disease phenotype, symptom predominance (especially itch severity for nemolizumab consideration), comorbidities (including asthma, food allergies, and ocular conditions), prior treatment responses, insurance coverage, administration preferences, anticipated adherence, treatment goals, and previous biologic experience—with biologic-naive patients typically receiving broader consideration, whereas those with prior biologic exposure require careful evaluation of previous response patterns, reasons for discontinuation, and strategic selection of agents with different mechanisms to potentially overcome therapeutic plateaus.